polystyrene sulfate

Networked: 5 relevant articles (3 outcomes, 0 trials/studies)

1.	Abensur Vuillaume, Laure: 1 article (04/2021)
2.	Boivin, Jean-Marc: 1 article (04/2021)
3.	Frimat, Luc: 1 article (04/2021)
4.	Girerd, Nicolas: 1 article (04/2021)
5.	Lamiral, Zohra: 1 article (04/2021)
6.	Rossignol, Patrick: 1 article (04/2021)
7.	Senninger, Lisa: 1 article (04/2021)
8.	Sanjanwala, Rohan: 1 article (01/2020)
9.	Sidhu, Kiran: 1 article (01/2020)
10.	Zieroth, Shelley: 1 article (01/2020)

1.	Hyperkalemia 04/01/2021 - "Sodium polystyrene sulfate was frequently seen as an appropriate first-line treatment for hyperkalemia (45%). " 06/01/2015 - "Little D, Nee R, Abbott K, et al. Cost utility analysis of sodium polystyrene sulfate vs. potential alternatives for chronic hyperkalemia. " 11/01/1994 - "Transient treatment with sodium polystyrene sulfate after enalapril withdrawal improved the hyperkalemia and renal function, but PRA and PA levels were low. "
2.	Heart Failure 01/01/2020 - "Patiromer and SZC have been studied in heart failure and both agents have demonstrated the ability to maintain normokalemia for extended periods of time with improved side effect profiles than existing potassium binders such as sodium polystyrene sulfate, though no direct comparisons have occurred. "
3.	Necrosis 07/01/2009 - "Colonic necrosis due to sodium polystyrene sulfate (Kayexalate)."

1.	Sodium
2.	Potassium
3.	Enalapril
4.	patiromer
5.	polystyrene sulfonic acid (sodium polystyrene sulfonate)